Want to join the conversation?
Medical devices company $TFX said the results of its pre-clinical intravascular study highlighted Arrow PICC with Chlorag ard Technology and its ability to significantly reduce thrombus formation when compared to competitive non-eluting antithrombogenic technologies. The eluting technology showed the best outcomes after a 30-day dwell time.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.